ストックスクリーナーアプリを入手
4.01
5.20%
-0.22
アフターアワーズ：
4.20
0.19
+4.74%
前日終値:
$4.23
開ける：
$4.01
24時間の取引高:
232.36K
Relative Volume:
0.46
時価総額：
$60.24M
収益：
-
当期純損益:
$-64.47M
株価収益率:
-0.6483
EPS:
-6.1852
ネットキャッシュフロー:
$-52.33M
1週間 パフォーマンス:
-17.15%
1か月 パフォーマンス:
-28.14%
6か月 パフォーマンス:
-75.50%
1年 パフォーマンス:
-85.20%
1日の値動き範囲:
$3.965
$4.198
1週間の範囲:
$3.965
$4.89
52週間の値動き範囲:
$3.965
$30.70
Jasper Therapeutics Inc Stock (JSPR) Company Profile
名前
Jasper Therapeutics Inc
セクター
電話
(650) 549-1400
住所
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
4.01 | 60.24M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-09-09 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-08 | 開始されました | BTIG Research | Buy |
| 2024-06-27 | 開始されました | Stifel | Buy |
| 2024-05-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-03 | 開始されました | Evercore ISI | Outperform |
| 2024-03-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-18 | 開始されました | TD Cowen | Outperform |
| 2023-08-11 | 開始されました | CapitalOne | Overweight |
| 2022-02-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Credit Suisse | Outperform |
| 2021-10-21 | 開始されました | William Blair | Outperform |
| 2021-10-20 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-13 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Jasper Therapeutics Inc (JSPR) 最新ニュース
JSPR stock touches 52-week low at $4.54 amid market challenges By Investing.com - Investing.com South Africa
JSPR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Jasper Therapeutics Inc Files For Common Stock Offering Of Up To $100 MillionSEC Filing - MarketScreener
DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World
Jasper Therapeutics inks new sales agreement, ends previous deal By Investing.com - Investing.com South Africa
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $62.50 - Defense World
Jasper Therapeutics inks new sales agreement, ends previous deal - Investing.com
Jasper Therapeutics Files $300 Million Mixed Shelf -March 19, 2025 at 05:08 pm EDT - Marketscreener.com
Jasper Therapeutics Signs New Sales Agreement with Jefferies - TipRanks
Jasper Therapeutics terminates Cantor sales agreement -March 19, 2025 at 04:53 pm EDT - Marketscreener.com
Jasper Therapeutics files for mixed shelf offering of up to $300 mln -March 19, 2025 at 04:17 pm EDT - Marketscreener.com
(JSPR) On The My Stocks Page - news.stocktradersdaily.com
Jasper Therapeutics’ (JSPR) Buy Rating Reiterated at HC Wainwright - Defense World
Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics - TipRanks
FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald - Defense World
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains Buy rating, $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones - TipRanks
Jasper Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Equities Analysts Set Expectations for JSPR Q1 Earnings - Defense World
Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study - MSN
JSPRJasper Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Jasper Therapeutics Presents Updated Clinical Data on Briquilimab at AAAAI 2025 Annual Meeting - Nasdaq
Jasper Therapeutics Presents Clinical and Preclinical - GlobeNewswire
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - Yahoo Finance UK
Can Jasper Therapeutics' Briquilimab Transform Chronic Urticaria Treatment? New Clinical Data Revealed - Stock Titan
Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab’s Clinical Progress and Financial Stability - TipRanks
Jasper Therapeutics Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Jasper Therapeutics, Inc. SEC 10-K Report - TradingView
Jasper Therapeutics to present briquilimab study at AAD Meeting - Investing.com India
Jasper Therapeutics to present briquilimab study at AAD Meeting By Investing.com - Investing.com South Africa
Jasper Therapeutics Announces Late-Breaking Briquilimab - GlobeNewswire
Can Jasper's Briquilimab Data for Chronic Urticaria Transform Treatment Outcomes? - StockTitan
Jasper Therapeutics Reports Promising Clinical Progress - TipRanks
Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating - TipRanks
Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab - TipRanks
Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23) - TipRanks
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings To Watch: Life Time (LTH) Reports Q4 Results Tomorrow - The Globe and Mail
Jasper Therapeutics to Present at Upcoming March Investor Conferences - The Manila Times
Jasper Therapeutics Sets March Conference Circuit to Showcase Mast Cell Disease Breakthroughs - StockTitan
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes CSU stock outlook - Investing.com
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes CSU stock outlook - Investing.com India
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.44 Consensus PT from Analysts - Defense World
Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
What To Expect From RE/MAX’s (RMAX) Q4 Earnings - The Globe and Mail
Jasper Therapeutics stock holds $70 target at JMP Securities By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Down 11.1% in January - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - Nasdaq
Jasper Therapeutics Inc (JSPR) 財務データ
収益
当期純利益
現金流量
EPS
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):